NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024
RADNOR, Pa., Aug. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter and year to date 2024 financial results after the market closes on Wednesday, August 14, 2024, via press release, which will be available on the Company's website at . The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day.
NRx制药公司（纳斯达克：NRXP）于2024年8月14日周三股市收盘后通过新闻稿公布其2024年第二季度和截至当年日期的财务业绩，该新闻稿将在公司网站上公布。 该公司将于当天下午4:30 ET召开电话会议，讨论财务业绩以及提供公司的最新动态。
A live webcast of the conference call will be available on the Company's website at . Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-800-717-1738 or internationally +1-646-307-1865.
该电话会议的现场网络直播将在公司网站上提供。无法加入网络直播的参与者可以通过电话加入会议，国内拨打+1-800-717-1738，国际拨打+1-646-307-1865。
About NRx Pharmaceuticals, Inc.
关于NRx制药公司
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx制药公司是一家临床阶段的生物制药公司，利用其NMDA技术平台开发治疗中枢神经系统疾病的药物，包括自杀性双相情感障碍、慢性疼痛和创伤后应激障碍。该公司正在开发NRX-101，FDA指定的自杀性治疗难以耐受的双相情感障碍和慢性疼痛的突破性疗法，计划在患有双相情感障碍、自杀倾向或坐立不安症状的患者中提交加速批准药品申请(NDA)。NRX-101有望成为慢性疼痛的非阿片类治疗，并可用于复杂的尿路感染的治疗。
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx制药公司最近宣布，基于美国国立卫生研究院(nih)的严格临床试验结果和法国卫生管理局的新数据共享协议，正计划提交一项关于NRX-100（IV胡椒酮）治疗自杀性抑郁症的新药申请。NRX制药公司获得美国FDA提供NRX-100开发快速通道的认可，作为治疗急性自杀的一部分。
About HOPE Therapeutics, Inc.
关于HOPE Therapeutics，Inc.
HOPE Therapeutics, Inc. () is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
HOPE Therapeutics, Inc.（）是一家医疗服务公司，开发了一系列最佳临床实践网络诊所，为患有自杀性抑郁症及相关疾病的患者提供胡椒酮等 lifesaving therapies，该公司的数字治疗平台是为了增强和保留NMDA-targeted药物疗法的临床效益而设计的。
SOURCE NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc.消息来源